Collaboration and License Agreements - ModernaTX, Inc - Additional Information (Details) - USD ($) $ in Thousands |
1 Months Ended | ||||
|---|---|---|---|---|---|
Jan. 31, 2023 |
Jun. 30, 2026 |
Dec. 31, 2025 |
Jun. 30, 2025 |
Dec. 31, 2024 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Deferred revenue | $ 54,690 | $ 28,467 | $ 32,291 | $ 94,063 | |
| ModernaTX, Inc | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Deferred revenue | 9,300 | ||||
| ModernaTX, Inc | Collaboration and License Agreement | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Upfront payment received | $ 35,000 | ||||
| Upfront consideration, pre-paid research and development service fees | 5,000 | ||||
| Deferred revenue | 9,300 | 9,300 | |||
| Amount due from agreement | $ 0 | $ 0 | |||
| ModernaTX, Inc | Collaboration and License Agreement | Maximum | |||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
| Contingent milestone payments receivable | $ 1,200,000 |